1 results match your criteria: "University Cancer Center (UCC) 'Carl Gustav Carus' TU Dresden[Affiliation]"
Oncotarget
December 2017
University Cancer Center (UCC) 'Carl Gustav Carus' TU Dresden, Tumor Immunology, Dresden, Germany.
As the expression of a tumor associated antigen (TAA) is commonly not restricted to tumor cells, adoptively transferred T cells modified to express a conventional chimeric antigen receptor (CAR) might not only destroy the tumor cells but also attack target-positive healthy tissues. Furthermore, CAR T cells in patients with large tumor bulks will unpredictably proliferate and put the patients at high risk of adverse side effects including cytokine storms and tumor lysis syndrome. To overcome these problems, we previously established a modular CAR technology termed UniCAR: UniCAR T cells can repeatedly be turned on and off via dosing of a target module (TM).
View Article and Find Full Text PDF